To validate the therapeutic potential of targeting TNKS1 and TNKS2, we first used a RNA interference approach to knockdown TNKS1 and TNKS2 in three commonly used HCC cell lines (HepG2, Hep40, and Huh7) and examined the effects on cell proliferation. This evidence concerns the gene TNKS and hepatocellular carcinoma.